作者
Zelalem Temesgen, Mariam Assi, FNU Shweta, Paschalis Vergidis, Stacey A Rizza, Philippe R Bauer, Brian W Pickering, Raymund R Razonable, Claudia R Libertin, Charles D Burger, Robert Orenstein, Hugo E Vargas, Raj Palraj, Ala S Dababneh, Gabrielle Chappell, Dale Chappell, Omar Ahmed, Reona Sakemura, Cameron Durrant, Saad S Kenderian, Andrew D Badley
发表日期
2020/11/1
期刊
Mayo Clinic Proceedings
卷号
95
期号
11
页码范围
2382-2394
出版商
Elsevier
简介
Objective
To assess the efficacy and safety of lenzilumab in patients with severe coronavirus disease 2019 (COVID-19) pneumonia.
Methods
Hospitalized patients with COVID-19 pneumonia and risk factors for poor outcomes were treated with lenzilumab 600 mg intravenously for three doses through an emergency single-use investigational new drug application. Patient characteristics, clinical and laboratory outcomes, and adverse events were recorded. We also identified a cohort of patients matched to the lenzilumab patients for age, sex, and disease severity. Study dates were March 13, 2020, to June 18, 2020. All patients were followed through hospital discharge or death.
Results
Twelve patients were treated with lenzilumab; 27 patients comprised the matched control cohort (untreated). Clinical improvement, defined as improvement of at least 2 points on the 8-point ordinal clinical endpoints scale, was observed …
学术搜索中的文章
Z Temesgen, M Assi, FNU Shweta, P Vergidis… - Mayo Clinic Proceedings, 2020